|
Inflammatory dermatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, the defect in the epidermal barrier and the resulting inflammatory skin disease that develops in mice lacking FGFR1 and FGFR2 in keratinocytes were further aggravated upon additional loss of FGFR3.
|
31830366 |
2020 |
|
Cholangiocarcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report the first case with cholangiocarcinoma harboring <i>FGFR2-BICC1</i> who is sensitive to sorafenib therapy.
|
31807010 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The NGS assay showed that the tumor had a <i>FGFR2-BICC1</i> rearrangement.
|
31807010 |
2019 |
|
Laryngeal Squamous Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To determine the frequency of the genotype of signal transducer and activator of transcription protein 3 (STAT3) rs744166, sirtuin (SIRT1) rs12778366, fibroblast growth factor (FGFR2) rs2981582, and advanced glycosylation end product-specific receptor (RAGE) rs1800625 gene polymorphisms in patients with laryngeal squamous cell carcinoma (LSCC).
|
31781300 |
2019 |
|
Perihilar Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SPRY4 expression can be induced by ectopic FGFR2 activation in PHCC.
|
31761616 |
2019 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AA genotype and A allele of P21 and TT genotypes and T allele of FGFR2 were significantly more frequent and were associated with an increased risk of early-onset of breast cancer (95%CI: 2.54 and 1.59; 2.63 and 1.64, respectively).
|
31759353 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
AA genotype and A allele of P21 and TT genotypes and T allele of FGFR2 were significantly more frequent and were associated with an increased risk of early-onset of breast cancer (95%CI: 2.54 and 1.59; 2.63 and 1.64, respectively).
|
31759353 |
2019 |
|
Hypospadias
|
0.220 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to investigate expression patterns and transcription levels of FGF8, FGF10, and FGF Receptor 2 (FGFR2) in patients with hypospadias compared to normal controls.
|
31718875 |
2019 |
|
Congenital Abnormality
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with hypospadias consistently showed aberrant immunohistochemical staining patterns for FGF8/FGF10/FGFR2 in epidermis and dermis compared to patients without penile malformation (p < 0.01 for all markers). qPCR displayed no difference in expression levels on mRNA level (FGFR2 p = 0.44, FGF8 p = 0.77, and FGF10 p = 0.17) comparing normal foreskin with foreskin from patients with hypospadias.Figure.
|
31718875 |
2019 |
|
Deformity
|
0.020 |
Biomarker
|
group |
BEFREE |
Patients with hypospadias consistently showed aberrant immunohistochemical staining patterns for FGF8/FGF10/FGFR2 in epidermis and dermis compared to patients without penile malformation (p < 0.01 for all markers). qPCR displayed no difference in expression levels on mRNA level (FGFR2 p = 0.44, FGF8 p = 0.77, and FGF10 p = 0.17) comparing normal foreskin with foreskin from patients with hypospadias.Figure.
|
31718875 |
2019 |
|
Penile hypospadias
|
0.020 |
Biomarker
|
disease |
BEFREE |
The objective of the study was to investigate expression patterns and transcription levels of FGF8, FGF10, and FGF Receptor 2 (FGFR2) in patients with hypospadias compared to normal controls.
|
31718875 |
2019 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
|
Microphakia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mouse lenses lacking FGFR2 exhibit microphakia and reduced ERK and AKT phosphorylation, widespread apoptosis, and defective lens fiber cell differentiation.
|
31691004 |
2019 |
|
Craniofacial dysostosis type 1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Inherited FGFR2 mutation in a Chinese patient with Crouzon syndrome and luxation of bulbus oculi provoked by trauma: a case report.
|
31640617 |
2019 |
|
Craniofacial Dysostosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Inherited FGFR2 mutation in a Chinese patient with Crouzon syndrome and luxation of bulbus oculi provoked by trauma: a case report.
|
31640617 |
2019 |
|
Craniosynostosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Crouzon syndrome (CS), which results from fibroblast growth factor receptor 2 mutations, is associated with craniosynostosis, exophthalmos, and other symptoms.
|
31640617 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More sophisticated patient selection strategies would help improve FGFR2-targeted therapies and combination therapy is considered the most promising approach for cancer patients with FGFR2 alterations.
|
31560229 |
2019 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
FGFR2 dysregulation occurs in numerous human solid tumors and overexpression is closely associated with tumor progression.
|
31560229 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
More sophisticated patient selection strategies would help improve FGFR2-targeted therapies and combination therapy is considered the most promising approach for cancer patients with FGFR2 alterations.
|
31560229 |
2019 |
|
Solid Neoplasm
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors.
|
31560229 |
2019 |
|
Malignant Pleural Mesothelioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We conclude that FGFR3 and FGFR4, but not FGFR1 or FGFR2, have prognostic significance in MPM and that FGFR expression is not sufficient to predict FGFR inhibitor response in MPM cell lines.
|
31527449 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Therefore, suppressing FGFR2 and enhancing miR-671-5p expression may be the right approaches for ESCC therapy.
|
31523191 |
2019 |
|
Solid Neoplasm
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
This first-in-human trial was conducted to determine the safety, tolerability, and maximum tolerated dose (MTD) of aprutumab ixadotin in patients with advanced solid tumors from cancer indications known to be FGFR2-positive.
|
31502117 |
2019 |
|
Craniofacial dysostosis type 1
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Crouzon syndrome is the result of a gain-of-function point mutation in FGFR2.
|
31463736 |
2019 |